|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Grady WM and Markowitz SD: The molecular
pathogenesis of colorectal cancer and its potential application to
colorectal cancer screening. Dig Dis Sci. 60:762–772.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Vishnoi A and Rani S: MiRNA biogenesis and
regulation of diseases: An overview. Methods Mol Bio. 1509:1–10.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Balacescu O, Sur D, Cainap C, Visan S,
Cruceriu D, Manzat-Saplacan R, Muresan MS, Balacescu L, Lisencu C
and Irimie A: The impact of miRNA in colorectal cancer progression
and its liver metastases. Int J Mol Sci. 19(3711)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ak S, Tunca B, Tezcan G, Cecener G, Egeli
U, Yilmazlar T, Ozturk E and Yerci O: MicroRNA expression patterns
of tumors in early-onset colorectal cancer patients. J Surg Res.
191:113–122. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kim YW, Kim EY, Jeon D, Liu JL, Kim HS,
Choi JW and Ahn WS: Differential microRNA expression signatures and
cell type-specific association with Taxol resistance in ovarian
cancer cells. Drug Des Deve Ther. 8:293–314. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yao T, Rao Q, Liu L, Zheng C, Xie Q, Liang
J and Lin Z: Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in cervical cancer. Virol J.
10(175)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang S, Gao B, Yang H, Liu X, Wu X and
Wang W: MicroRNA-432 is downregulated in cervical cancer and
directly targets FN1 to inhibit cell proliferation and invasion.
Oncol Lett. 18:1475–1482. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
D'Angelo D, Palmieri D, Mussnich P, Roche
M, Wierinckx A, Raverot G, Fedele M, Croce CM, Trouillas J and
Fusco A: Altered microRNA expression profile in human pituitary GH
adenomas: Down-regulation of miRNA targeting HMGA1, HMGA2, and
E2F1. J Clin Endocrinol Metab. 97:E1128–E1138. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jiang N, Chen WJ, Zhang JW, Xu C, Zeng XC,
Zhang T, Li Y and Wang GY: Downregulation of miR-432 activates
Wnt/β-catenin signaling and promotes human hepatocellular carcinoma
proliferation. Oncotarget. 6:7866–7879. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lv D, Zhen Z and Huang D: MicroRNA-432 is
downregulated in osteosarcoma and inhibits cell proliferation and
invasion by directly targeting metastasis-associated in colon
cancer-1. Exp Ther Med. 17:919–926. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chen L, Kong G, Zhang C, Dong H, Yang C,
Song G, Guo C, Wang L and Yu H: MicroRNA-432 functions as a tumor
suppressor gene through targeting E2F3 and AXL in lung
adenocarcinoma. Oncotarget. 7:20041–20053. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang T, Du M, Zhang W, Bai H, Yin L, Chen
W, He X and Chen Q: MicroRNA-432 suppresses invasion and migration
via E2F3 in nasopharyngeal carcinoma. Onco Targets Ther.
12:11271–11280. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Reddy KB: MicroRNA (miRNA) in cancer.
Cancer Cell Int. 15(38)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Eashita D and Nitai PB: MicroRNA-432
contributes to dopamine cocktail and retinoic acid induced
differentiation of human neuroblastoma cells by targeting NESTIN
and RCOR1 genes. FEBS Lett. 588:1706–1714. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nemlich Y, Greenberg E, Ortenberg R,
Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L,
Prieto VG, et al: microRNA-mediated loss of ADAR1 in metastatic
melanoma promotes tumor growth. J Clin Invest. 123:2703–2718.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Zlotnik A and Yoshie O: The chemokine
superfamily revisited. Immunity. 36:705–716. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang W, Wang H, Sun M, Deng X, Wu X, Ma
Y, Li M, Shuoa SM, You Q and Miao L: CXCL5/CXCR2 axis in tumor
microenvironment as potential diagnostic biomarker and therapeutic
target. Cancer Commun (Lond). 40:69–80. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hu B, Fan H, Lv X, Chen S and Shao Z:
Prognostic significance of CXCL5 expression in cancer patients: A
meta-analysis. Cancer Cell Int. 18(68)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16(70)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH,
Feng H, Zheng MH, Zhao JK and Lu AG: CXCL5 induces tumor
angiogenesis via enhancing the expression of FOXD1 mediated by the
AKT/NF-κB pathway in colorectal cancer. Cell Death Dis.
10(178)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Speetjens FM, Kuppen PJ, Sandel MH, Menon
AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ and
Nagelkerke JF: Disrupted expression of CXCL5 in colorectal cancer
is associated with rapid tumor formation in rats and poor prognosis
in patients. Clin Cancer Res. 14:2276–2284. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kawamura M, Toiyama Y, Tanaka K, Saigusa
S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y and Kusunoki M:
CXCL5, a promoter of cell proliferation, migration and invasion, is
a novel serum prognostic marker in patients with colorectal cancer.
Eur J Cancer. 48:2244–2251. 2012.PubMed/NCBI View Article : Google Scholar
|
